00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Eli Lilly received U.S. Food and Drug Administration approval for its once-daily weight-loss pill,
00:07setting up competition with Novo Nordisk's Wegevy pill, which launched earlier this year,
00:11according to the Wall Street Journal. Lilly aims to expand its position in the $70 billion-plus GLP-1
00:16market as analysts project its pill found Deo could generate $21 billion in global sales by
00:202030, compared with $4 billion for Wegevy's pill. Novo's pill showed about 16.6% weight loss in
00:26trials versus 12.4% for Lilly's. Lilly plans to emphasize convenience with fewer dosing
00:30restrictions. Both companies are targeting patients who prefer pills over injections.
00:34For all things money, visit Benzinga.com.
Comments